

# Autonomic dysfunction causes disability in Parkinson disease: a prospective study

Alberto Romagnolo<sup>1</sup>, Aristide Merola<sup>2</sup>, Michela Rosso<sup>2</sup>, Maurizio Zibetti<sup>1</sup>, Ritika Suri<sup>2</sup>, Zoe Berndt<sup>2</sup>, Carlo Alberto Artusi<sup>1</sup>, Francesca Dematteis<sup>1</sup>, Mario Giorgio Rizzone<sup>1</sup>, Alberto J. Espay<sup>2</sup>, Leonardo Lopiano<sup>1</sup> <sup>1</sup> Department of Neuroscience "Rita Levi Montalcini", University of Turin, Italy

<sup>2</sup> University of Cincinnati, Cincinnati, Ohio, USA

## BACKGROUND

Dysautonomia represents a frequent but still underrecognized feature of Parkinson disease (PD)[1], with a detrimental effect on patients' disability[2]. What remains to be clarified is how the rate of progression of dysautonomia is independently related to the worsening of activities of daily living (ADL) and quality of life (QoL).

# **OBJECTIVES**

To evaluate the extent to which progression of dysautonomia in PD impairs ADL and QoL and the effect of orthostatic hypotension (OH) on clinical disability, falls and health care utilization.

	ADL Deterioration		QoL Deterioration	
	Odds Ratio (95% CI)	Ρ	Odds Ratio (95% CI)	Ρ
SCOPA-AUT Total Score	2.193 (1.096-4.780) <b>.(</b>	028	2.967 (1.230-7.154)	.015
Gastrointestinal domain	2.050 (1.050-4.556) .0	042	3.210 (1.400-7.362)	.006
Urinary-sexual domain	1.377 (0.619-3.063) .4	434	2.227 (1.080-5.057)	.046
Cardiovascular domain	1.332 (0.545-3.259) .	530	3.763 (1.492-9.490)	.005
Thermoregulatory domain	1.623 (0.718-3.669) .2	245	3.205 (1.391-7.388)	.006
Pupillomotor domain	3.235 (0.663-5.795) .′	147	2.015 (0.975-3.817)	.098

**Table 1. Impact of autonomic symptoms on deterioration of activities of daily living and quality of life** (data adjusted for disease duration, MoCA and MDS-UPDRS-III scores modification)

## **MATERIALS AND METHODS**

We recruited 131 PD patients into a 12-month, prospective, observational cohort study. Clinical measures included the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Scale for Outcomes in PD-Autonomic (SCOPA-AUT) (total score and different autonomic domains), and orthostatic blood pressure measurements. Dysautonomia was defined as impairment in more than one autonomic domain. Worsening of autonomic symptoms was defined as  $\geq$  1 increase in the SCOPA-AUT score during follow-up.

## RESULTS

After 12 months, complete data were available for 122 patients. The overall severity of autonomic symptoms worsened by 20% during follow-up, with SCOPA-AUT changing from  $12.85 \pm 8.52$  to  $15.38 \pm 9.22$ . (p<0.001). Gastrointestinal symptoms deteriorated in 51.6% of patients, urinary/sexual in 59.0%, thermoregulatory in 45.1%, cardiovascular in 29.5%, and pupillomotor in



11.5%. The prevalence of OH increased from 31.1% to 46.7% (p<0.001), of which 38.6% were asymptomatic. After adjusting for disease duration, cognitive impairment, and motor severity, worsening of autonomic symptoms was associated with deterioration in ADL (OR:2.1; p=0.028) and QoL (OR:2.9; p=0.015). The association between the worsening of autonomic domains and ADL deterioration or QoL impairment is summarized in Table 1. Compared to patients without OH (Figure 1), symptomatic OH resulted in a 4-fold higher risk of ADL deterioration, a 7-fold higher risk of QoL deterioration, a 7-fold higher risk of falls and a 6-fold higher risk of higher utilization of health care. Asymptomatic OH resulted in a 5-fold higher risk of ADL deterioration, a 3-fold higher risk of QoL deterioration, a 6-fold higher risk of falls and a 12-fold higher risk of higher utilization of health care ( $p \le 0.002$ ). The presence of concurrent SH did not yield any effect on ADL or QoL.

### CONCLUSIONS

Autonomic symptoms severity progression and OH (even if asymptomatic) independently worsened ADL and QoL, Figure 1. Impact of symptomatic/asymptomatic orthostatic hypotension and supine hypertension on ADL and quality of life (data adjusted for disease duration, MoCA and MDS-UPDRS-III scores modification)

#### REFERENCES

 Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010;25:704-9.
Tomic S, Rajkovaca I, Pekic V, et al. Impact of autonomic dysfunctions on the quality of life in Parkinson's disease patients. Acta Neurol Belg 2017;117:207-11.

3. Müller B, Assmus J, Herlofson K, et al. Importance of motor vs.

#### confirming that dysautonomia is an important determinant



non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord 2013;19:1027-32.